1. Session 9: Management of COPD
Leonard D. Hudson, M.D., F.C.C.P. 
CHEST 
Volume 85, Issue 6, Pages 76S-81S (June 1984)
DOI: /chest.85.6_Supplement.76S
Copyright © 1984 The American College of Chest Physicians Terms and Conditions

2. Figure 2
Improvement in spirometry prebronchodilator. FEV1 = forced expiratory volume in 1 s; FVC=forced vital capacity. Patients receiving methylprednisolone had a greater improvement in airflow than did those receiving placebo.
(from Albert et al, Ann Intern Med 1980; 92:753-58, by permission)
CHEST  , 76S-81SDOI: ( /chest.85.6_Supplement.76S)
Copyright © 1984 The American College of Chest Physicians Terms and Conditions

3. Figure 4
Survival data from both the National Institutes of Health sponsored Nocturnal Oxygen Therapy trial and the British Medical Research Council study. The display shows that in the Nocturnal Oxygen Therapy Trial, continuous oxygen therapy (COT) had improved survival over nocturnal oxygen therapy (NOT). Nocturnal oxygen therapy was similar to oxygen used for approximately 15 hours per day in the MRC study and this had better survival than the MRC control group. (Figure supplied by Dr. David Flenley.)
CHEST  , 76S-81SDOI: ( /chest.85.6_Supplement.76S)
Copyright © 1984 The American College of Chest Physicians Terms and Conditions